Results 171 to 180 of about 10,941,841 (309)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Complete Issue Volume 4 Issue 1

Journal of the Scholarship of Teaching and Learning, 2012
Editor, Journal of the Scholarship of Teaching and Learning
doaj  

Volume 2, Issue 4

Emerging Infectious Diseases, 1996
doaj   +1 more source

Corrigendum to "Investigations on the microstructure and properties of yttria and silicon carbide reinforced aluminium composites" [Heliyon Volume 9, Issue 4, April 2023, Article e15462]. [PDF]

Heliyon
Shantharaman PP, Anandakrishnan V, Sathish S, Ravichandran M, Naveenkumar R, Jayasathyakawin S, Rajesh S.   +6 more
europepmc   +1 more source

v. 72, issue 12, February 4, 2005 [PDF]

, 2005

core   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Complete Issue Volume 11 Issue 4

Journal of the Scholarship of Teaching and Learning, 2012
Editor, Journal of the Scholarship of Teaching and Learning
doaj  

Corrigendum to "Pregnancies in Women With Kidney Failure on Home Dialysis in the United States" [<i>Kidney International Reports</i> Volume 9, Issue 4, April 2024, Pages 907-918]. [PDF]

Kidney Int Rep
Shah S, Weinhandl E, Leonard AC, Rachwal B, Verma P, Perl J, Christianson AL.   +6 more
europepmc   +1 more source

v. 80, issue 4, March 1, 2013 [PDF]

, 2013

core   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source